Actively Recruiting
Sphenopalatine Block Versus BOTOX in Management of Chronic Migraine
Led by Cairo University · Updated on 2025-05-16
64
Participants Needed
1
Research Sites
19 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This trial compares the efficacy and safety of sphenopalatine ganglion block (SPGB) and intramuscular BOTOX injection in chronic migraine.
CONDITIONS
Official Title
Sphenopalatine Block Versus BOTOX in Management of Chronic Migraine
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 to 65 years
- Both sexes
- Chronic migraine with headaches on 15 or more days per month for at least 3 months, including 8 or more days meeting migraine criteria or responding to migraine-specific treatment according to International Classification of Headache Disorders-3 Beta
You will not qualify if you...
- Patients with medication overuse headache
- Bleeding disorders
- Abnormal neurological examination
- History of allergy to local anesthetics or BOTOX
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Cairo University
Cairo, Egypt, 12613
Actively Recruiting
Research Team
M
Mohamed E Abdel Fattah, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here